These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24423438)

  • 1. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
    Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
    J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
    Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
    J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
    Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
    PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
    Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
    Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
    Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
    Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
    Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
    Gao H; Jiang Q; Han Y; Peng J; Wang C
    Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
    Vroling L; van der Veldt AA; de Haas RR; Haanen JB; Schuurhuis GJ; Kuik DJ; van Cruijsen H; Verheul HM; van den Eertwegh AJ; Hoekman K; Boven E; van Hinsbergh VW; Broxterman HJ
    Angiogenesis; 2009; 12(1):69-79. PubMed ID: 19212818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
    Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
    Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
    Bousquet G; Varna M; Ferreira I; Wang L; Mongiat-Artus P; Leboeuf C; de Bazelaire C; Faivre S; Bertheau P; Raymond E; Germain S; Janin A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1183-93. PubMed ID: 24061866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
    Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D
    J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
    Duignan IJ; Corcoran E; Pennello A; Plym MJ; Amatulli M; Claros N; Iacolina M; Youssoufian H; Witte L; Samakoglu S; Schwartz J; Surguladze D; Tonra JR
    Neoplasia; 2011 Jan; 13(1):49-59. PubMed ID: 21245940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.